In the BioHarmony Drug Report Database

"Preview" Icon

Amikacin

Amikin, Arikayce (amikacin) is a small molecule pharmaceutical. Amikacin was first approved as Amikin on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, burns, central nervous system infections, and endocarditis amongst others in the USA. It has been approved in Europe to treat respiratory tract infections. Amikacin sulfate’s patents are valid until 2035-05-15 (FDA).

 

Trade Name

 

Arikayce liposomal
 

Common Name

 

amikacin
 

ChEMBL ID

 

CHEMBL177
 

Indication

 

acinetobacter infections, bacterial infections, burns, central nervous system infections, endocarditis, escherichia coli infections, infectious bone diseases, infectious skin diseases, intraabdominal infections, klebsiella infections, mycobacterium infections, proteus infections, pseudomonas infections, respiratory tract infections, serratia infections, soft tissue infections, staphylococcal infections, surgical wound infection, urinary tract infections
 

Drug Class

 

Antibiotics obtained from Streptomyces kanamyceticus (related to kanamycin)

Image (chem structure or protein)

Amikacin structure rendering